BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 256 filers reported holding BRIDGEBIO PHARMA INC in Q2 2024. The put-call ratio across all filers is 0.32 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $635,074 | -6.4% | 25,072 | +14.2% | 0.00% | 0.0% |
| Q1 2024 | $678,694 | -18.5% | 21,950 | +6.4% | 0.00% | -33.3% |
| Q4 2023 | $832,833 | +80.6% | 20,630 | +17.9% | 0.00% | +50.0% |
| Q3 2023 | $461,238 | +53.3% | 17,491 | 0.0% | 0.00% | +100.0% |
| Q2 2023 | $300,845 | +28.4% | 17,491 | +23.7% | 0.00% | 0.0% |
| Q1 2023 | $234,358 | +117.6% | 14,135 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $107,709 | +7.7% | 14,135 | +40.0% | 0.00% | 0.0% |
| Q3 2022 | $100,000 | +8.7% | 10,097 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $92,000 | -9.8% | 10,097 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $102,000 | -44.0% | 10,097 | -7.7% | 0.00% | 0.0% |
| Q4 2021 | $182,000 | -51.7% | 10,935 | +36.1% | 0.00% | -50.0% |
| Q3 2021 | $377,000 | -23.1% | 8,035 | -0.1% | 0.00% | -33.3% |
| Q2 2021 | $490,000 | +59.1% | 8,045 | +61.1% | 0.00% | +50.0% |
| Q1 2021 | $308,000 | – | 4,995 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $373,797,000 | 67.28% |
| Darwin Global Management, Ltd. | 2,090,149 | $128,753,000 | 25.21% |
| Affinity Asset Advisors, LLC | 577,500 | $35,574,000 | 12.08% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $1,913,356,000 | 9.64% |
| Perceptive Advisors | 7,756,928 | $477,827,000 | 6.04% |
| Opaleye Management Inc. | 583,767 | $35,960,000 | 5.28% |
| MIZUHO MARKETS AMERICAS LLC | 171,923 | $10,590,000 | 4.93% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $1,639,853,000 | 4.88% |
| Fernwood Investment Management, LLC | 151,085 | $9,307,000 | 3.42% |
| HHLR ADVISORS, LTD. | 5,362,014 | $330,300,000 | 3.26% |